Gabapentin as add-on treatment for somatoform disorder: A case report

Clinical Neuropharmacology

Volumn 35, Issue 1, 2012, Pages 45-46

  Guglielmo, Riccardo ^a   Martinotti, Giovanni ^b   Janiri, Luigi ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

add on treatment; gabapentin; somatoform disorder

Indexed keywords

DELORAZEPAM; ESCITALOPRAM; GABAPENTIN; PAROXETINE; SULPIRIDE; VENLAFAXINE;

ADD ON THERAPY; ADULT; ANXIETY DISORDER; ARTICLE; CASE REPORT; CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE THERAPY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GALACTORRHEA; HUMAN; HYPERPROLACTINEMIA; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SOMATOFORM DISORDER;

ADULT; AMINES; ANTICONVULSANTS; ANTIMANIC AGENTS; CYCLOHEXANECARBOXYLIC ACIDS; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; PSYCHIATRIC STATUS RATING SCALES; SOMATOFORM DISORDERS;

EID: 84855858763     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e31823e669b     Document Type: Article

References (14)

1. Kroenke K. Efficacy of treatment for somatoform disorders: a review of randomized controlled trials. Psychosom Med 2007;69:881-888. (Pubitemid 350158831)
2. Luo YL, Zhang MY, Wu WY, et al. A randomized double-blind clinical trial on analgesic efficacy of fluoxetine for persistent somatoform pain disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:1522-1525.
3. Han C, Pae CU, Lee BH, et al. Fluoxetine versus sertraline in the treatment of patients with undifferentiated somatoform disorder: a randomized, open-label, 12-week, parallel-group trial. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:437-444. (Pubitemid 351178961)
4. Han C, Pae CU, Lee BH, et al. Venlafaxine versus mirtazapine in the treatment of undifferentiated somatoform disorder: a 12-week prospective, open-label, randomized, parallel-group trial. Clin Drug Investig 2008;28:251-261. (Pubitemid 351414749)
5. García-Campayo J, Sanz-Carrillo C. Gabapentin for the treatment of patients with somatization disorder. J Clin Psychiatry 2001;62:474. (Pubitemid 32717882)
6. Harnack D, Scheel M, Mundt A, et al. Pregabalin in patients with antidepressant treatment-resistant somatoform disorders: a case series. J Clin Psychopharmacol 2007;27:537-539. (Pubitemid 47415069)
7. Gee NS, Brown JP, Dissanayake VU, et al. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 1996;271:5768-5776. (Pubitemid 26083915)
8. Mula M, Pini S, Cassano GB. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J Clin Psychopharmacol 2007;27:263-272. (Pubitemid 46763308)
9. Martinotti G, di Nicola M, Frustaci A, et al. Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: a multi-centre, randomized, single-blind comparison trial. Addiction 2010;105:288-299.
10. Martinotti G, Di Nicola M, Tedeschi D, et al. Efficacy and safety of pregabalin in alcohol dependence. Adv Ther 2008;25:608-618.
11. Lo HS, Yang CM, Lo HG, et al. Treatment effects of gabapentin for primary insomnia. Clin Neuropharmacol 2010;33:84-90.
12. Di Nicola M, Tedeschi D, Martinotti G, et al. Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder: a 16-week case series. J Clin Psychopharmacol 2011;31:675-677.
13. McLean MJ. Gabapentin. Epilepsia 1995;36(Suppl 2):S73-S86.
14. Ben-Menachem E, Persson LI, Hedner T. Selected CSF biochemistry and gabapentin concentrations in the CSF and plasma in patients with partial seizure after a single dose of gabapentin. Epilepsy Res 1992;11:45-49.